NHS North of England Branded Medicines Tranche A & Annual Tranche

Tender description

NHS Framework for North of England Branded Medicines - Tranche A and Annual Tranche.<br/>Offer reference number: CM/PHR/20/5606<br/>CM/PHR/20/5606/01 - NHS Framework for North of England Branded Medicines - Tranche A. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/20/5606/02 - NHS Framework for North of England Branded Medicines - Annual Tranche. Period of framework: 1 March 2023 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months<br/>CM/PHR/20/5606/03 - NHS National Framework Agreement for the supply of Risankizumab for South of England and London. Period of framework: 1 March 2023 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months Lot 1: CM/PHR/20/5606/01 - NHS Framework for North of England Branded - Tranche A Lot 1 - CM/PHR/20/5606/01 - NHS Framework for North of England Branded Medicines - Tranche A. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: CM/PHR/20/5606/02 - NHS Framework for North of England Branded - Annual Tranche CM/PHR/20/5606/02 - NHS Framework for North of England Branded Medicines - Annual Tranche. Period of framework: 1 March 2023 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: CM/PHR/20/5606/03 - NHS Supply of Risankizumab for South of England & London Lot 3 - CM/PHR/20/5606/03 - NHS National Framework Agreement for the supply of Risankizumab for South of England and London. Period of framework: 1 March 2023 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents